What is the recommended management for multiple thyroid nodules?

Management of Multiple Thyroid Nodules

For patients with multiple thyroid nodules, use TIRADS risk stratification to guide selective FNA of up to 4 nodules based on size and sonographic features, prioritizing the largest and most suspicious nodules, as the per-patient cancer risk remains similar to solitary nodules (approximately 15%) but per-nodule risk decreases with increasing nodule number.

Risk Stratification Using TIRADS

The cornerstone of managing multiple thyroid nodules is systematic ultrasound-based risk assessment using Thyroid Imaging Reporting and Data Systems (TIRADS) 1. This standardized approach minimizes unnecessary biopsies while identifying clinically significant malignancies.

Key Principles for Multiple Nodules:

• Cancer prevalence is similar between patients with solitary nodules (14.8%) and multiple nodules (14.9%), but individual nodule risk decreases as nodule count increases 2
• In multinodular disease, 72% of cancers occur in the largest nodule and 46% are multifocal 2
• Nodules <1 cm generally warrant surveillance only, unless subcapsular or associated with suspicious lymph nodes 1

Selective FNA Strategy

Biopsy up to 4 nodules when multiple nodules exceed 10 mm to adequately exclude cancer 2. Prioritize nodules based on:

Highest Priority Features (in order):

1. Largest nodule (most likely to harbor malignancy in multinodular glands)
2. Solid composition with microcalcifications (highest risk combination)
3. Male gender (increases individual nodule risk)
4. Hypoechogenicity, irregular margins, taller-than-wide shape 3, 4

Risk Stratification by Sonographic Features:

• Highest risk (up to 48%): Solitary solid nodule with punctate calcifications in men
• Lowest risk (<3%): Non-calcified predominantly cystic nodule in women 2

Important caveat: FNA remains the gold standard for preoperative diagnosis 1, but cytology has limitations—follicular carcinoma appears indeterminate, medullary carcinoma is diagnosed in only ~50% of cases, and cancer subtyping is rarely reliable 1.

Initial Workup Algorithm

1. Measure TSH first to identify functional nodules requiring different management 5, 3
2. Perform dedicated thyroid ultrasound with TIRADS classification of all nodules
3. Apply size and feature criteria:
   • Nodules ≥10 mm with high-risk TIRADS features → consider FNA
   • Nodules <10 mm → surveillance unless subcapsular or suspicious nodes present 1
4. Select up to 4 nodules for FNA based on size and sonographic risk 2

Management Based on Cytology Results

Benign (Bethesda II):

• Surveillance with minimal or long-interval follow-up imaging 6
• Most require no treatment

Indeterminate (Bethesda III-IV):

• Consider molecular testing to improve preoperative risk determination and reduce unnecessary surgery 6
• Molecular testing indicated in 20-30% of biopsies with indeterminate cytology 3

Malignant or Suspicious (Bethesda V-VI):

• Surgical planning based on extent of disease
• Hemithyroidectomy now commonly considered for small, isolated cancers rather than routine near-total thyroidectomy 6
• Active surveillance is an option for small volume, isolated papillary thyroid microcarcinomas in select patients 1, 6

Common Pitfalls to Avoid

1. Do not biopsy all nodules indiscriminately—this leads to unnecessary procedures and costs without improving outcomes 1
2. Do not assume multinodular goiter is protective—cancer risk per patient is equivalent to solitary nodules 2
3. Do not ignore the largest nodule—it harbors malignancy in 72% of multinodular cancer cases 2
4. Do not rely on cytology for cancer subtyping—it is unreliable and unnecessary for initial management 1
5. Avoid FNA of high-risk nodules <1 cm unless subcapsular or lymph node involvement present 1

Long-Term Surveillance

For nodules not meeting FNA criteria or with benign cytology:

• Cystic or spongiform nodules suggest benign process requiring no additional testing 3
• Follow-up intervals should be risk-adapted based on initial TIRADS classification 4
• Most benign nodules are clinically insignificant and safely managed with observation 3, 6

The evidence strongly supports a conservative, risk-stratified approach that prevents overdiagnosis and overtreatment of indolent disease while identifying the small subset (~10%) requiring intervention 3, 6, 4.